Moreover, Ki67 is one of the 21 prospectively selected genes of the Oncotype DXTM assay used to predict the risk of recurrence in a node-negative, tamoxifen-treated breast cancer population enrolled in the National Surgical Adjuvant Breast and Bowel Project B-14 (NSABP B-14). The gene discussed is MKI67; the disease is breast carcinoma.